Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model

FASEB Journal

Volumn 30, Issue 1, 2016, Pages 370-379

  Saigusa, Takamitsu ^a,b   Dang, Yujing ^b   Mullick, Adam E ^c   Yeh, Steve T ^c   Zile, Michael R ^a,b   Baicu, Catalin F ^a,b   Bell, P Darwin ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotide; Hypertension; Polycystic kidney disease; Renin angiotensin system

Indexed keywords

ANGIOTENSINOGEN; ANTISENSE OLIGONUCLEOTIDE; KIDNEY RENIN; LISINOPRIL; MESSENGER RNA; POLYCYSTIN 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN;

ADULT; ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; HORMONE INHIBITION; HORMONE SYNTHESIS; KIDNEY CYST; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; GENETICS; KIDNEY; KIDNEY POLYCYSTIC DISEASE; METABOLISM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; FEMALE; KIDNEY; LISINOPRIL; MALE; MICE; MICE, INBRED C57BL; POLYCYSTIC KIDNEY DISEASES; TRPP CATION CHANNELS;

EID: 84974831449     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.15-279299     Document Type: Article

References (42)

1. Torres, V. E., Harris, P. C., and Pirson, Y. (2007) Autosomal dominant polycystic kidney disease. Lancet 369, 1287-1301
2. Saigusa, T., and Bell, P. D. (2015) Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) 30,195-207
3. Chapman, A. B., Johnson, A., Gabow, P. A., and Schrier, R. W. (1990) The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323, 1091-1096
4. Graham, P. C., and Lindop, G. B. (1988) The anatomy of the reninsecreting cell in adult polycystic kidney disease. Kidney Int. 33, 1084-1090
5. Chapman, A. B., Stepniakowski, K., and Rahbari-Oskoui, F. (2010) Hypertension in autosomal dominant polycystic kidney disease. Adv. Chronic Kidney Dis. 17, 153-163
6. Cao, Z., and Cooper, M. E. (2001) Role of angiotensin II in tubulointerstitial injury. Semin. Nephrol. 21, 554-562
7. Keith, D. S., Torres, V. E., Johnson, C. M., and Holley, K. E. (1994) Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am. J. Kidney Dis. 24, 491-498
8. Zafar, I., Tao, Y., Falk, S., McFann, K., Schrier, R. W., and Edelstein, C. L. (2007) Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am. J. Physiol. Renal Physiol. 293, F854-F859
9. Jafar, T. H., Stark, P. C., Schmid, C. H., Strandgaard, S., Kamper, A. L., Maschio, G., Becker, G., Perrone, R. D., and Levey, A. S.; ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group. (2005) The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 67, 265-271
10. McPherson, E. A., Luo, Z., Brown, R. A., LeBard, L. S., Corless, C. C., Speth, R. C., and Bagby, S. P. (2004) Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 15, 493-500
11. Schrier, R. W., Abebe, K. Z., Perrone, R. D., Torres, V. E., Braun, W. E., Steinman, T. I., Winklhofer, F. T., Brosnahan, G., Czarnecki, P. G., Hogan, M. C., Miskulin, D. C., Rahbari-Oskoui, F. F., Grantham, J. J., Harris, P. C., Flessner, M. F., Bae, K. T., Moore, C. G., and Chapman, A. B.; HALT-PKD Trial Investigators. (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2255-2266
12. Torres, V. E., Abebe, K. Z., Chapman, A. B., Schrier, R. W., Braun, W. E., Steinman, T. I., Winklhofer, F. T., Brosnahan, G., Czarnecki, P. G., Hogan, M. C., Miskulin, D. C., Rahbari-Oskoui, F. F., Grantham, J. J., Harris, P. C., Flessner, M. F., Moore, C. G., and Perrone, R. D.; HALT-PKD Trial Investigators. (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2267-2276
13. Torres, V. E., Donovan, K. A., Scicli, G., Holley, K. E., Thibodeau, S.N., Carretero, O. A., Inagami, T., McAteer, J. A., and Johnson, C. M. (1992) Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int. 42, 364-373
14. Loghman-Adham, M., Soto, C. E., Inagami, T., and Cassis, L. (2004) The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol. 287, F775-F788
15. Kobori, H., Nangaku, M., Navar, L. G., and Nishiyama, A. (2007) The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251-287
16. Ravichandran, K., Ozkok, A., Wang, Q., Mullick, A. E., and Edelstein, C. L. (2015) Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2. Am. J. Physiol. Renal Physiol. 308, F349-F357
17. Saigusa, T., Dang, Y., Bunni, M. A., Amria, M. Y., Steele, S. L., Fitzgibbon, W. R., and Bell, P. D. (2015) Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease. Physiol. Rep. 3, e12405
18. Piontek, K. B., Huso, D. L., Grinberg, A., Liu, L., Bedja, D., Zhao, H., Gabrielson, K., Qian, F., Mei, C., Westphal, H., and Germino, G. G. (2004) A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J. Am. Soc. Nephrol. 15, 3035-3043
19. Hayashi, S., and McMahon, A. P. (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244, 305-318
20. Sas, K. M., Yin, H., Fitzgibbon, W. R., Baicu, C. F., Zile, M. R., Steele, S. L., Amria, M., Saigusa, T., Funk, J., Bunni, M. A., Siegal, G. P., Siroky, B. J., Bissler, J. J., and Bell, P. D. (2015) Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. Am. J. Physiol. Renal Physiol. 309, F79-F87
21. Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., Hung, G., Bennett, C. F., and Cleveland, D. W. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044
22. Tanimoto, K., Sugiyama, F., Goto, Y., Ishida, J., Takimoto, E., Yagami, K., Fukamizu, A., and Murakami, K. (1994) Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 269, 31334-31337
23. Matsusaka, T., Niimura, F., Shimizu, A., Pastan, I., Saito, A., Kobori, H., Nishiyama, A., and Ichikawa, I. (2012) Liver angiotensinogen is the primary source of renal angiotensin II. J. Am. Soc. Nephrol. 23, 1181-1189
24. Tomita, N., Morishita, R., Higaki, J., Aoki, M., Nakamura, Y., Mikami, H., Fukamizu, A., Murakami, K., Kaneda, Y., and Ogihara, T. (1995) Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 26, 131-136
25. Makino, N., Sugano, M., Ohtsuka, S., and Sawada, S. (1998) Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31, 1166-1170
26. Bennett, C. F., and Swayze, E. E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293
27. Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M. J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., Tribble, D. L., Flaim, J. D., and Crooke, S. T. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006
28. Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., and Weitz, J. I., for the FXI-ASO TKA Investigators. (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372, 232-240
29. Pohl, M., Kaminski, H., Castrop, H., Bader, M., Himmerkus, N., Bleich, M., Bachmann, S., and Theilig, F. (2010) Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J. Biol. Chem. 285, 41935-41946
30. Kamiyama, M., Farragut, K. M., Garner, M. K., Navar, L. G., and Kobori, H. (2012) Divergent localization of angiotensinogen mRNA and protein in proximal tubule segments of normal rat kidney. J. Hypertens. 30, 2365-2372
31. Kobori, H., and Urushihara, M. (2013) Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflugers Arch. 465, 3-12
32. Kobori, H., Harrison-Bernard, L. M., and Navar, L. G. (2002) Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 61, 579-585
33. Ahmad, S., Varagic, J., Groban, L., Dell'Italia, L. J., Nagata, S., Kon, N. D., and Ferrario, C. M. (2014) Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr. Hypertens. Rep. 16, 429
34. Wei, C. C., Hase, N., Inoue, Y., Bradley, E. W., Yahiro, E., Li, M., Naqvi, N., Powell, P. C., Shi, K., Takahashi, Y., Saku, K., Urata, H., Dell'italia, L. J., and Husain, A. (2010) Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Invest. 120, 1229-1239
35. Célérier, J., Cruz, A., Lamandé, N., Gasc, J. M., and Corvol, P. (2002) Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 39, 224-228
36. Wu, C., Lu, H., Cassis, L. A., and Daugherty, A. (2011) Molecular and pathophysiological features of angiotensinogen: a mini review. N. Am. J. Med. Sci. 4,183-190
37. Rockey, D. C., Bell, P. D., and Hill, J. A. (2015) Fibrosis: a common pathway to organ injury and failure. N. Engl. J. Med. 372, 1138-1149
38. Chapin, H. C., and Caplan, M. J. (2010) The cell biology of polycystic kidney disease. J. Cell Biol. 191, 701-710
39. Torres, V. E., Boletta, A., Chapman, A., Gattone, V., Pei, Y., Qian, Q., Wallace, D. P., Weimbs, T., and Wüthrich, R. P. (2010) Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin. J. Am. Soc. Nephrol. 5, 1312-1329
40. Lancaster, M. A., and Gleeson, J. G. (2010) Cystic kidney disease: the role of Wnt signaling. Trends Mol. Med. 16, 349-360
41. Wallace, D. P. (2011) Cyclic AMP-mediated cyst expansion. Biochim. Biophys. Acta 1812, 1291-1300
42. Wolf, G., and Neilson, E. G. (1993) Angiotensin II as a renal growth factor. J. Am. Soc. Nephrol. 3, 1531-1540